• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Spyre Therapeutics (SYRE) Shares Climbed After Its Latest Update

    Simply Wall St·09/14/2026 07:17:13
    Listen to the news

    Spyre Therapeutics (SYRE) just reported 12 week Phase 2 SKYLINE data for SPY003 in moderately to severely active ulcerative colitis, hitting its primary endpoint and key secondary measures with a safety profile aligned to the IL 23 class.

    Spyre Therapeutics has seen very strong momentum play out over the past year, with a year to date share price return of 196.27% and a very large 1 year total shareholder return, even though the 30 day share price return is down 12.57% from recent highs.

    Scan how Spyre Therapeutics fits into a broader set of immunology and biotech opportunities by reviewing our curated list of 15 high quality undiscovered gems that are positioned around major clinical catalysts.

    Spyre Therapeutics now trades near recent highs after a sharp run and a short-term pullback. Investors may consider whether to commit capital at this level or wait for a cooler entry as the valuation picture comes into focus.

    Preferred Price-to-Book of 8.4x for Spyre Therapeutics: Is it justified?

    Spyre Therapeutics trades on a P/B ratio of 8.4x against a last close of $90.60. This places the stock at a rich valuation level compared to the broader US Biotechs industry while still below its closer peer group.

    The price to book multiple compares Spyre Therapeutics' market value to the accounting value of its net assets. For an early stage biotech with no revenue and ongoing losses, investors often lean on this metric because there are no earnings or sales to plug into P/E or P/S ratios.

    Here, the P/B of 8.4x sits well above the wider US Biotechs industry average of 2.3x. This suggests the market is paying a premium relative to many other drug developers. At the same time, the multiple is below the 11.5x peer average cited in the data, which indicates that within Spyre Therapeutics' closer comparison set, its valuation is not at the top end.

    Compared with the sector at large, Spyre Therapeutics looks expensive on a P/B basis. This implies investors are assigning a higher value to its pipeline and balance sheet than they do for the typical biotech stock. Against its more targeted peer group, the P/B ratio appears more restrained, pointing to a valuation that is still elevated but not out of line with similar clinical stage businesses focused on inflammatory and rheumatic conditions.

    Result: Price-to-book of 8.4x (OVERVALUED).

    See what the numbers say about this price — find out in our valuation breakdown.

    Still, the story around Spyre Therapeutics can change quickly if future trial readouts disappoint or if funding conditions tighten for loss making biotechs.

    Find out about the key risks to this Spyre Therapeutics narrative.

    Next Steps

    Mixed signals around Spyre Therapeutics can feel confusing. Move quickly, review the underlying data, and decide where you land on the balance of risks and rewards by checking the 1 key reward and 5 important warning signs.

    Looking for more investment ideas beyond Spyre Therapeutics?

    If Spyre Therapeutics has your attention, do not stop there. Broaden your watchlist, compare different risk profiles, and give yourself more options before making your next move.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.